We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
ADLM 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Test Kit to Measure TTV Titer and Assessing Results Using Algorithm Could Improve COVID-19 Diagnosis

By LabMedica International staff writers
Posted on 08 Nov 2021
Image: Test Kit to Measure TTV Titer and Assessing Results Using Algorithm Could Improve COVID-19 Diagnosis (Photo courtesy of IMT-USP)
Image: Test Kit to Measure TTV Titer and Assessing Results Using Algorithm Could Improve COVID-19 Diagnosis (Photo courtesy of IMT-USP)

A study has shown that levels of Torquetenovirus (TTV), an apparently inoffensive virus considered an indicator of immunodepression, tend to be higher in people infected by SARS-CoV-2.

The new study by researchers at the University of São Paulo (São Paulo, Brazil) suggests that TTV load in people infected by SARS-CoV-2 can be used as a marker of COVID-19 severity and recovery. TTV is one of the viruses most frequently found in the human organism. It is also common in monkeys and domestic animals. Its presence has not been associated with any known disease, but its excessive replication is a sign that something is wrong with the immune system. The correlation between high TTV load and immunosuppression has been used in medicine in certain contexts, such as monitoring transplant patients who take medication to prevent rejection of the transplanted organ.

In the study, the researchers analyzed samples from patients to investigate how the elimination of SARS-CoV-2 varies over time in different body fluids, such as blood, urine and saliva. All patients included in the study had mild or moderate COVID-19. TTV and SARS-CoV-2 viral loads were measured in saliva samples.

“We used analyzed samples from 91 patients diagnosed with SARS-CoV-2 by RT-PCR, and from 126 people with flu symptoms who tested negative. We found TTV titer to be higher in subjects infected by the novel coronavirus. The higher the titer, the longer they remained sick. Symptoms disappeared as viral load decreased. In uninfected subjects, TTV titer remained stable throughout the symptomatic period,” said Maria Cássia Mendes-Correa, a professor at the Medical School (FM-USP). “The results showed that TTV can indeed serve as a marker of the progression and outcome of this disease. The more symptomatic the patient, the higher the TTV load in the sample.”

Related Links:
University of São Paulo 

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Online QC Software
Acusera 24•7
Automated Coagulation Analyzer
Hemolumi H6
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240

Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
PURITAN MEDICAL